Evidence map›Paper›PMID 42717664›Full record

ReviewMycoses2026

Hidden Mould in the Air: A Practical Narrative Mini-Review of Invasive Mould Infection Prevention for High-Risk Patients and Clinicians.

Angelika Bauer, Cornelia Lass-Flörl, Stephan Steixner, Oliver Cornely, Ilana Reinhold, Laura Walti, International Society for Human and Animal Mycology (ISHAM) Working Group for Patient Representation and Advocacy in Invasive Fungal Infections

Abstract readReview
In one paragraph

Review in Mycoses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Angelika BauerInstitute of Hygiene and Medical Microbiology, European Excellence Centre of Medical Mycology, Medical University of Innsbruck, Innsbruck, Austria.ORCID https://orcid.org/0000-0003-2413-3425
Cornelia Lass-FlörlInstitute of Hygiene and Medical Microbiology, European Excellence Centre of Medical Mycology, Medical University of Innsbruck, Innsbruck, Austria.
Stephan SteixnerInstitute of Hygiene and Medical Microbiology, European Excellence Centre of Medical Mycology, Medical University of Innsbruck, Innsbruck, Austria.
Oliver CornelyInstitute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0001-9599-3137
Ilana ReinholdInstitute of Translational Research, CECAD, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Laura WaltiDepartment of Infectious Diseases, Inselspital, Berne University Hospital, University of Berne, Berne, Switzerland.
International Society for Human and Animal Mycology (ISHAM) Working Group for Patient Representation and Advocacy in Invasive Fungal Infections

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Airborne mould spores, including those of the Aspergillus species, are ubiquitous both indoors and outdoors. While they are generally harmless, inhaled spores can cause severe infections, particularly invasive pulmonary aspergillosis, in patients with impaired immune defences. Allergic manifestations such as asthma arise by different mechanisms and are not covered. This narrative mini-review summarises key evidence and guideline recommendations for healthcare teams and provides practical, patient-friendly advice by highlighting clinical and infection-prevention considerations. As there is no safe exposure threshold or minimum infectious dose for individual patients, prevention focuses on reducing avoidable exposure during high-risk periods. These high-risk periods typically refer to medical conditions such as prolonged neutropenia, the early post-transplant period, and high-dose corticosteroid therapy. Furthermore, prevention also focuses on optimising hospital environmental controls by implementing high-efficiency particulate air filter filtration, protective rooms and construction dust containment, alongside antifungal prophylaxis when indicated. The most impactful measures at home are preventing and rapidly remediating visible mould and dampness, avoiding high-spore activities such as composting, handling potting soil, and working with demolition or renovation dust, and maintaining simple hygiene practices that reduce dust reservoirs. This narrative mini-review also summarises what the literature can and cannot provide. Although Aspergillus species account for most of the available evidence, the same exposure-reduction principles apply to other environmentally acquired moulds, including Mucorales, Fusarium species and Scedosporium species.

Indexed as

Air MicrobiologyFungiInfection ControlInvasive Fungal InfectionsAntifungal AgentsEnvironmental ExposureHumansImmunocompromised HostInvasive Pulmonary AspergillosisAntifungal AgentsaspergillosisAspergillus fumigatusenvironmental exposurehaematopoietic stem cell transplantationhigh‐risk patientsimmunocompromised hostinfection controlinvasive fungal infections

Identifiers

PMID42717664
PMCPMC13559205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.